This study aims to analyze whether cyclic glycine proline is involved in the self-healing process during the early stages of metabolic dysfunction in people with type 2 diabetes

Evaluation of the cause-effect relationship of plasma cyclic glycine proline and the manifestations of type 2 diabetes mellitus (T2DM) and its associated vascular complications

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN76855091

Enrollment

Registered

2024-07-31

Start date

2021-05-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine

Interventions

During a single hospital visit, fasting blood samples and spot urine samples are taken for biological analysis. Glucose metabolism is evaluated by measuring fasting glucose concentration, HBA1c (%), t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female participants, 45 to 80 years of age 2. Medical history and clinical diagnosis of T2DM either without or with medical history and clinical diagnosis of dyslipidaemia, hypertension and/or clinical diagnosis of foot DPN

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Pregnancy related T2DM and/or hypertension 3. Poorly controlled glucose metabolism (fasting glucose >15 mmol/L) 4. T2DM with severe complications such as diabetes ketoacidosis, stage 4 diabetic nephropathy and diabetic foot ulcer 5. Other causes of hypertension and chronic kidney diseases 6. Drug, injury or neurological condition induced peripheral neuropathy 7. Medical history of degenerative conditions 8. Cognitive impairment and major mental health issues 9. Severe depression and anxiety

Design outcomes

Primary

Measure	Time frame
During a single hospital visit, the fasting blood samples and spot urine samples are taken for biological analysis. As a primary outcome, glucose metabolism is evaluated by measuring fasting glucose concentration, HBA1c (%), triglyceride/glucose index.	—

Secondary

Measure	Time frame
Measured at a single time point: 1. Blood pressure is evaluated by measuring systolic and diastolic blood pressure 2. Foot diabetic peripheral neuropathy is evaluated by measuring foot sensation using Semmes-Weinstein monofilament test, vibration and warm/cold perceptions tests 3. Kidney function is evaluated by measuring urine concentration of albumin, albumin/creatinine ratio, plasma urea nitrogen and its ratio with plasma creatinine	—

Measure

Time frame

Measured at a single time point: 1. Blood pressure is evaluated by measuring systolic and diastolic blood pressure 2. Foot diabetic peripheral neuropathy is evaluated by measuring foot sensation using Semmes-Weinstein monofilament test, vibration and warm/cold perceptions tests 3. Kidney function is evaluated by measuring urine concentration of albumin, albumin/creatinine ratio, plasma urea nitrogen and its ratio with plasma creatinine

—

Countries

China

Contacts

Public ContactJian Guan

jian.guan@thecgplab.com+64 210366863

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026